接受免疫检查点抑制剂治疗的肺癌患者接种新型冠状病毒mRNA疫苗的安全性与免疫原性:日本多中心观察性研究
日本九家医院多中心观察性研究纳入126例正在接受免疫检查点抑制剂治疗的肺癌患者,评估接种新冠病毒mRNA疫苗后免疫相关不良事件(irAE)发生率与抗S-IgG抗体反应。接种后irAE发生率为5.6%,低于未接种时的预测发生率35%;血清阳转率96.7%低于对照组的100%,抗体水平显著更低(p < 0.001)。作者结论为接种安全、未增加irAE,但免疫原性较低,需进一步评估。
要点
- 接种后irAE发生率为5.6%(95%CI 2.3%-11.1%),低于未接种时的预测发生率35%。
- 接种前irAE发生率为20.6%(95%CI 13.9%-28.8%),接种后未出现既往irAE加重。
- 肺癌患者S-IgG血清阳转率96.7%,低于对照组的100%,抗体水平显著更低(p < 0.001)。
核心结论
- 正在接受免疫检查点抑制剂治疗的肺癌患者接种mRNA疫苗安全,未增加irAE发生率,但疫苗免疫原性较低,需进一步评估。
研究设计与样本
- 日本九家医院开展的多中心观察性研究,纳入126例年龄≥20岁、在首次接种前4周至第二次接种后4周内正在接受免疫检查点抑制剂治疗的肺癌患者,2021年5月至11月入组,随访至2021年12月。
- 主要终点为任何级别irAE的发生率,以未接种时假设发生率35%为参照。
- 免疫原性通过检测针对新型冠状病毒的抗刺突(S)-IgG抗体水平评估。
主要发现
- 接种前任何级别irAE发生率为20.6%(95%CI 13.9%-28.8%),接种后为5.6%(95%CI 2.3%-11.1%),均低于未接种时的预测发生率35%。
- 接种后无患者出现既往irAE加重。
- 肺癌患者S-IgG血清阳转率为96.7%,对照组为100%,肺癌患者抗体水平显著低于对照组(p < 0.001)。
局限性
- 原文结论指出疫苗免疫原性较低,需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with cancer have been prioritized for vaccination against severe acute respiratory syndrome coronavirus 2. Nevertheless, there are limited data regarding the safety, efficacy, and risk of developing immune-related adverse events (irAEs) associated with mRNA vaccines in patients with lung cancer, especially those being actively treated with immune checkpoint inhibitors. METHODS: This multicenter observational study was conducted at nine hospitals in Japan. Patients with lung cancer (≥20 y) actively treated with immune checkpoint inhibitors between 4 weeks prefirst vaccination and 4 weeks postsecond vaccination were enrolled. The primary end point was the incidence of irAEs of any grade on the basis of an assumed incidence without vaccination rate of 35%. Immunogenicity was assessed by measuring anti-spike (S)-IgG antibody levels against severe acute respiratory syndrome coronavirus 2. RESULTS: A total of 126 patients with lung cancer (median age, 71 y; interquartile range, 65-74) were enrolled from May to November 2021 and followed up until December 2021. There were 26 patients (20.6%, 95% confidence interval: 13.9%-28.8%) and seven patients (5.6%, 95% confidence interval: 2.3%-11.1%) who developed irAEs of any grade pre- and postvaccination, respectively, which was lower than the predicted incidence without vaccination. None of the patients experienced exacerbation of preexisting irAE postvaccination. S-IgG antibodies were seroconverted in 96.7% and 100% of the patients with lung cancer and controls, respectively, but antibody levels were significantly lower in patients with lung cancer (p < 0.001). CONCLUSIONS: Patients with lung cancer who were actively treated with ICIs were safely vaccinated without an increased incidence of irAEs; however, their vaccine immunogenicity was lower. This requires further evaluation.
引用
- Hibino M, Uryu K, Takeda T, et al. Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan. J Thorac Oncol. 2022. PMID: 35752437. doi:10.1016/j.jtho.2022.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。